The global in vitro diagnostics (IVD) market is estimated to have reached $69.2bn in 2018. The largest sector of the IVD market in 2018 was point of care diagnostics segment, generating sales of $19.4bn in 2018, which accounted for 28.0% of overall IVD sales.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 204-page report you will receive 180 charts– all unavailable elsewhere.
The 204-page report provides clear detailed insight into the leading in vitro diagnostics (IVD) companies. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• In Vitro Diagnostics (IVD) revenues in 2017 and 2018 by Class:
• Point-of-Care
• Clinical Chemistry
• Immunochemistry
• Hematology
• Microbiology
• Genetic Testing
• Others
• In Vitro Diagnostics (IVD) revenue forecast for 2019, 2024 and 2029 by Class:
• Point-of-Care
• Clinical Chemistry
• Immunochemistry
• Hematology
• Microbiology
• Genetic Testing
• Others
• This report profiles and discusses the selected leading in vitro diagnostics (IVD) companies:
• Abbott Laboratories
• Arkray, Inc.
• Becton, Dickinson and Company (BD)
• bioMérieux SA
• Bio-Rad Laboratories, Inc.
• Dako (Agilent Technologies)
• Danaher Corporation
• Genomic Health
• Laboratory Corporation of America (LabCorp)
• MDxHealth
• Myriad Genetics
• QIAGEN
• Roche
• Siemens AG
• Sysmex Corporation
• Thermo Fisher Scientific
• Other companies
• This report discusses sales and recent performance analysis, key products, strengths and challenges, historical revenues, revenue forecast, market share forecast, mergers and acquisition (M&A) activity, strategic collaborations
• Analysis of factors that drive and restrain the in vitro diagnostics (IVD) market.
• Key Questions Answered by this Report:
• Who are the leading IVD manufacturers?
• What factors are driving and restraining growth for the leading IVD manufacturers?
• How have the leading IVD manufacturers performed financially in recent years?
• Which IVD manufacturers will experience revenue growth over the coming years?
• What are the strength and weakness of the leading IVD manufacturers?
• What strategies have IVD manufacturers been implementing for sales growth in recent years?
Visiongain’s study is intended for anyone requiring commercial analyses for the leading in vitro diagnostics (IVD) companies. You find data, trends and predictions.
Buy our report today Medical Devices Leader Series: Top In Vitro Diagnostics (IVD) Market Analysis : Danaher Corporation, Abbott Laboratories, Bio-Rad Laboratories, Roche, Siemens AG, Sysmex, Other Companies.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 How This Report Delivers Information
1.2 Main Questions This Report Answers
1.3 Who is This Report for?
1.4 Methods of Research and Analysis
1.5 Frequently Asked Questions (FAQs)
1.6 Associated Visiongain Reports
1.7 About Visiongain
2. An Introduction to In Vitro Diagnostics
2.1 The In Vitro Diagnostics Market
2.1.1 The In Vitro Diagnostics Market in 2018
2.2 What are In Vitro Diagnostic (IVD) Tests?
2.3 Classifying In Vitro Diagnostics
2.3.1 The US Classification
2.3.2 The EC (European Commission) Classification
2.3.3 Regulatory Issues in the IVD Market
2.3.3.1 Regulation of IVD Tests
2.3.3.2 Lack of Clarity Can Be Costly
2.4 Types of IVD Test
2.4.1 Point of Care Diagnostics
2.4.2 Clinical Chemistry
2.4.3 Microbiology
2.4.3.1 Regulatory Differences with IVD Microbiology Tests
2.4.4 Haematology
2.4.5 Immunochemistry
2.4.6 Genetic Testing
2.5 The IVD Market: Overall Revenue Forecast to 2029
2.5.1 Market Drivers, 2019-2029
2.5.2 Market Restraints, 2019-2029
2.5.3 Future of the IVD Industry
2.6 Company Comparison
2.6.1 Fragmented Market
2.6.2 IVD Market: Leading Manufacturers in 2018
3. The Leading US in Vitro Diagnostic Companies, 2019-2029
3.1 Danaher Corporation
3.1.1 Sales and Recent Performance Analysis
3.1.2 Diagnostics
3.1.3 Key Products
3.1.4 Danaher Manufacturing Capabilities
3.1.5 Danaher IVD Segment: Strengths and Challenges
3.1.6 Danaher’s Life Sciences and Diagnostics Revenues
3.1.7 IVD Revenue Forecast, 2018-2029
3.1.8 Recent Mergers and Acquisition (M&A) Activity
3.2 Abbott Laboratories
3.2.1 Sales and Recent Performance Analysis
3.2.2 Abbott: Diagnostics Segment
3.2.2.1 In Vitro Diagnostics Products
3.2.3 Abbott IVD Segment: Strengths and Challenges
3.2.4 Abbott Diagnostics Historical Revenues, 2015-2017
3.2.5 IVD Revenue Forecast, 2019-2029
3.2.6 Recent M&A Activity and Strategic Collaborations
3.2.6.1 Collaboration with GSK
3.2.6.2 Collaboration with Merck
3.2.6.3 Acquisition of Alere, Inc.
3.3 Bio-Rad Laboratories, Inc.
3.3.1 Sales and Recent Performance Analysis
3.3.2 Clinical Diagnostics
3.3.2.1 In Vitro Diagnostics
3.3.3 IVD Revenue 2018
3.3.4 IVD Revenue Forecast, 2019-2029
3.3.5 Recent M&A Activity and Strategic Collaborations
3.3.6 Potential Bio-Rad Labs Takeover Seen in Near-Term
3.4 Becton, Dickinson and Company
3.4.1 Global Presence
3.4.2 Distribution
3.4.3 R&D
3.4.4 Sales and Recent Performance Analysis
3.4.4.1 Historical Sales Performance Analysis
3.4.5 BD Diagnostics Revenue
3.4.6 IVD Revenue Forecast, 2019-2029
3.4.7 Recent M&A Activity and Strategic Collaborations
3.5 Thermo Fisher Scientific
3.5.1 Historical Sales and Recent Performance Analysis
3.5.2 Clinical Diagnostics
3.5.3 Key Products
3.5.4 Thermo Fisher’s Manufacturing Capabilities
3.5.5 Thermo Fisher’s Diagnostics Revenues
3.5.6 IVD Revenue Forecast 2019-2029
3.5.7 Recent Mergers and Acquisition Activity
4. The Leading European In Vitro Diagnostic Companies, 2019-2029
4.1 Hoffmann-La Roche Ltd.
4.1.1 Global Presence
4.1.2 Sales and Recent Performance Analysis
4.1.3 Roche Diagnostics
4.1.4 R&D Capabilities
4.1.5 Growing Portfolio of Diagnostic Products
4.1.5.1 Exploring Strategies in the Neurological Sector
4.1.6 IVD Revenue Forecast 2019-2029
4.1.7 Recent M&A Activity and Strategic Collaborations
4.2 Siemens AG
4.2.1 Sales and Recent Performance, 2017
4.2.2 Siemens Healthcare
4.2.2.1 Siemens Diagnostics
4.2.2.2 Outperforming the Market
4.2.2.3 In Vitro Diagnostics
4.2.3 IVD Revenue Forecast 2019-2029
4.2.4 Recent M&A Activity and Strategic Collaborations
4.2.4.1 Partnership with ViiV Healthcare
4.2.4.2 Partnership with Tocagen
4.2.4.3 Acquisition of Fast Track Diagnostics
4.3 bioMérieux S.A.
4.3.1 Sales and Recent Performance, 2017
4.3.2 IVD Revenue Forecast 2019-2029
4.3.3 Recent M&A Activity and Strategic Collaborations
4.3.3.1 Partnership with GSK
4.3.3.2 Partnership with Ipsen
4.3.3.3 Partnership with Institute Merieux and Institute Pasteur
4.3.3.4 Collaboration with Hospices Civils de Lyon
4.3.3.5 Acquisition of ARGENE
4.3.3.6 Equity Interest in Knome
5. The Leading Japanese In Vitro Diagnostic Companies, 2019-2029
5.1 Sysmex Corporation
5.1.1 Global Presence and Distribution
5.1.2 Sales and Recent Performance Analysis
5.1.3 Sysmex Diagnostics
5.1.4 IVD Revenue Forecast 2019-2029
5.1.5 Recent M&A Activity and Strategic Collaborations
5.1.5.1 Acquisition of Katakura’s Research Institute of Biological Science
5.1.5.2 Collaboration with IDEXX Labs to Expand into Animal Diagnostics
5.2 Arkray, Inc.
5.2.1 Global Presence
5.2.2 R&D
5.2.3 IVD Product Portfolio
5.2.4 Sales and Recent Performance Analysis
5.2.5 IVD Revenue Forecast 2019-2029
6. Emerging In Vitro Diagnostic Companies, 2018
6.1 Pipeline and Other Companies: An Overview, 2018
6.2 Other Prominent In Vitro Diagnostic Players
6.3 Dako (Agilent Technologies)
6.3.1 Sales and Recent Performance Analysis
6.3.2 M&A Activity and Other Key Developments
6.4 Genomic Health, Inc.
6.4.1 Sales and Recent Performance Analysis
6.4.2 R&D Capabilities
6.4.2.1 TAILORx Clinical Trial
6.4.2.2 RxPonder Trial
6.4.2.3 Partnership with Oncomed
6.5 Laboratory Corporation of America (LabCorp)
6.5.1 Sales and Recent Performance Analysis
6.5.2 In Vitro Diagnostics
6.6 Recent M&A Activity and Other Key Developments
6.6.1 Non-Exclusive License Agreement with Merck
6.6.2 Acquisition of Genzyme Genetics
6.6.3 Partnership with ARCA Biopharma
6.7 MDxHealth, Inc.
6.7.1 Sales and Recent Performance Analysis, 2017
6.7.2 R&D Capabilities
6.7.3 In Vitro Diagnostics
6.7.3.1 PharmacoMDx
6.7.3.2 PredictMDx for Brain Cancer
6.7.3.3 PredictMDx for Colon Cancer
6.7.3.4 Partnership with GSK
6.8 Myriad Genetics, Inc.
6.8.1 Sales and Recent Performance Analysis
6.8.2 R&D Capabilities
6.8.3 In Vitro Diagnostics
6.8.3.1 Myriad RBM
6.8.4 M&A Activity and Recent Partnerships
6.8.4.1 Agreement with BioMarin Pharmaceutical
6.8.4.2 Acquisition of Myriad RBM
6.8.4.3 Strategic Debt Investment in Crescendo Bioscience
6.8.4.4 Agreement with Cephalon
6.8.4.5 Agreement with PharmaMar
6.9 QIAGEN N.V.
6.9.1 Sales and Recent Performance Analysis
6.9.2 Continued Expansion in the Emerging Markets
6.9.3 R&D Capabilities
6.9.3.1 More than 15 Projects to Co-Develop and Market Diagnostic Products
6.9.3.2 Provider of Choice for Molecular Diagnostic Tools
6.9.4 Recent M&A Activity and Other Developments
6.9.4.1 Acquisition of Cellestis Ltd.
6.9.4.2 Acquisition of Ipsogen
6.9.4.3 Partnership with Pfizer
6.9.4.4 Partnership with Eli Lilly
7. Other In-Vitro Diagnostic Companies, 2018
7.1 Hologic, Inc.
7.1.1 Sales and Recent Performance Analysis
7.1.2 In Vitro Diagnostics
7.1.3 Recent M&A Activity and Strategic Collaborations
7.2 Bayer AG
7.2.1 Sales and Recent Performance Analysis
7.2.2 In Vitro Diagnostics
7.2.3 Recent M&A Activity and Strategic Collaborations
7.3 Transasia Bio-Medicals Ltd.
7.3.1 In Vitro Diagnostics
7.3.2 Recent M&A Activity and Strategic Collaborations
7.4 PerkinElmer, Inc.
7.4.1 Sales and Recent Performance Analysis
7.4.2 In Vitro Diagnostics
7.4.3 Recent M&A Activity and Strategic Collaborations
7.5 DiaSorin S.p.A.
7.5.1 Sales and Recent Performance Analysis
7.5.2 In Vitro Diagnostics
7.5.3 Recent M&A Activity and Strategic Collaborations
7.6 Koninklijke Philips N.V.
7.6.1 Sales and Recent Performance Analysis
7.6.2 In Vitro Diagnostics
7.6.3 Recent M&A Activity and Strategic Collaborations
7.7 Illumina, Inc.
7.7.1 Sales and Recent Performance Analysis
7.7.2 In Vitro Diagnostics
7.7.3 Recent M&A Activity and Strategic Collaborations
7.8 Kem-en-tec Diagnostics A/S
7.8.1 In Vitro Diagnostics
7.8.2 Recent M&A Activity and Strategic Collaborations
8. Conclusions
8.1 In Vitro Diagnostics: Attractive Segment of the Healthcare Market
8.2 Big Pharma Dominated the IVD Market in 2018
8.3 The Rise of ‘Generic Medical Devices’
8.4 What Will Succeed in the IVD Market?
8.5 Small Companies Can Have a Big Impact on the Industry and Market to 2029
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
List of Tables
Table 2.1 IVD Revenues ($bn) and Market Shares (%) by Class, 2017-2018
Table 2.2 Advantages and Disadvantages of POC Diagnostics
Table 2.3 IVD Tests: Overall World Market and Submarket Revenue Forecasts ($bn), 2018, 2019, 2024 & 2029
Table 2.4 Leading Manufacturers: IVD Market Share (%), 2018
Table 2.5 Leading Companies in the IVD Market: Net Sales ($bn) and Market Shares (%), 2018
Table 3.1 Danaher: Key Facts
Table 3.2 Danaher: Net Sales ($bn) and Revenue Shares (%) by Business Segment, 2017
Table 3.3 Danaher: Life Sciences & Diagnostics Revenue ($bn), AGR (%), 2015-2017
Table 3.4 Danaher: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
Table 3.5 Abbott: Key Facts
Table 3.6 Abbott: Net Sales ($bn) and Revenue Shares (%) by Business Segment, 2017
Table 3.7 Abbott: Revenues ($bn) and Revenue Shares (%) by Geographical Region, 2017
Table 3.8 Abbott: Diagnostics Revenue ($bn), AGR (%), 2015-2017
Table 3.9 Abbott: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
Table 3.10 Bio-Rad: Key Facts
Table 3.11 Bio-Rad: Clinical Diagnostics Revenue ($bn), AGR (%) 2015-2017
Table 3.12 Bio-Rad: IVD Revenue Forecast ($bn), Growth (%), CAGR (%), Market Share (%) 2019-2029
Table 3.13 BD: Key Facts
Table 3.14 Becton Dickinson: Net Sales ($bn) and Revenue Shares (%) by Sector, 2017
Table 3.15 BD: Diagnostics Revenue ($bn), AGR (%) 2015-2017
Table 3.16 BD: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
Table 3.17 Thermo Fisher: Key Facts
Table 3.18 Thermo Fisher: IVD Sales ($bn), AGR (%), 2015-2017
Table 3.19 Thermo Fisher: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
Table 4.1 Roche: Key Facts
Table 4.2 Roche: Revenue ($bn) and Revenue Shares (%) by Sector, 2017
Table 4.3 Roche Diagnostics: Revenue ($bn) and Revenue Shares (%) by Sector, 2017
Table 4.4 Roche Diagnostics: Marketed Diagnostic Products
Table 4.5 Roche: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
Table 4.6 Siemens: Key Facts
Table 4.7 Siemens: Revenue ($bn) and Revenue Shares (%) by Sector, 2017
Table 4.8 Siemens: Revenue ($bn) and Revenue Shares (%) by Region, 2017
Table 4.9 Siemens: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
Table 4.10 bioMérieux: Key Facts
Table 4.11 bioMérieux: Revenue ($bn) and Revenue Shares (%) by Sector, 2017
Table 4.12 bioMérieux: Clinical Applications Revenue ($bn) and Revenue Shares (%) by Sector, 2017
Table 4.13 bioMérieux: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
Table 5.1 Sysmex: Key Facts
Table 5.2 Sysmex: Revenue ($bn) by Sector, 2017
Table 5.3 Sysmex: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
Table 5.4 Arkray: Key Facts
Table 5.5 Arkray: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
Table 6.1 Agilent: Revenue ($bn) and Revenue Shares (%) by Sector, 2017
Table 6.2 Dako: Marketed Diagnostic Products, 2017
Table 6.3 Genomic Health: Revenue ($m) and Revenue Shares (%) by Reporting Segment, 2017
Table 6.4 Genomic Health: R&D Expense ($m) and R&D Expense as a Percentage of Sales (%), 2013-2017
Table 6.5 LabCorp: Revenues ($bn) and Revenue Shares (%) by Reporting Segment, 2017
Table 6.6 Selected List of LabCorp’s Menu of Diagnostic Products, 2017
Table 6.7 MDxHealth: Revenue ($m) and Revenue Shares (%) by Reporting Segment, 2017
Table 6.8 MDxHealth: In Vitro Diagnostics Pipeline, 2017
Table 6.9 Myriad: Revenue ($m) and Revenue Shares (%) by Sector, 2017
Table 6.10 Myriad Molecular Diagnostics: Revenue ($m) and Revenue Shares (%) by Product, 2017
Table 6.11 Myriad Molecular Diagnostics: Revenue ($m) and Revenue Shares (%) by Sector, 2017
Table 6.12 Myriad: Biomarker Product Portfolio, 2017
Table 6.13 Myriad: Diagnostic Products, 2017
Table 6.14 QIAGEN: Revenue ($m) and Revenue Shares (%) by Customer Class, 2017
Table 6.15 QIAGEN: Revenue ($m) and Revenue Shares (%) by Region, 2017
Table 6.16 QIAGEN: Selected List of Co-development Projects
Table 6.17 QIAGEN: Selected Marketed Diagnostic Products
Table 6.18 QIAGEN: Recent M&A Activity
Table 6.19 Other Companies Operating in the IVD Market, 2018
Table 7.1 Hologic, Inc.: Key Facts
Table 7.2 Hologic, Inc.: Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
Table 7.3 Hologic, Inc.: Product Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
Table 7.4 Hologic, Inc.: Clinical Diagnostics Revenue ($bn), AGR (%) 2015-2017
Table 7.5 Bayer AG: Key Facts, 2017
Table 7.6 Bayer AG: Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
Table 7.7 Transasia Bio-Medicals Ltd: Key Facts, 2017
Table 7.8 PerkinElmer, Inc.: Key Facts, 2017
Table 7.9 PerkinElmer, Inc.: Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
Table 7.10 PerkinElmer, Inc.: Product Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
Table 7.11 PerkinElmer, Inc.: Clinical Diagnostics Revenue ($bn), AGR (%) 2015-2017
Table 7.12 DiaSorin: Key Facts, 2017
Table 7.13 DiaSorin: Revenue ($m) and Revenue Shares (%) by Geography, 2017
Table 7.14 Koninklijke Philips N.V.: Key Facts, 2017
Table 7.15 Koninklijke Philips N.V.: Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
Table 7.16 Koninklijke Philips N.V.: Diagnosis & Treatment Revenue ($bn), AGR (%) 2015-2017
Table 7.17 Koninklijke Philips N.V.: Diagnosis & Treatment Product Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
Table 7.18 Illumina, Inc.: Key Facts
Table 7.19 Illumina, Inc.: Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
Table 7.20 Kem-en-tec Diagnostics A/S: Key Facts
Table 8.1 Leading IVD Manufacturers by Company Type, 2018
List of Figures
Figure 2.1 IVD Market ($bn) by Class 2018
Figure 2.2 IVD: Overall Market ($bn) Forecast, 2018, 2019, 2024 & 2029
Figure 2.3 IVD Market: Drivers and Restraints, 2019-2029
Figure 2.4 Leading Companies in the IVD Market: Net Sales ($bn), 2018
Figure 2.5 Leading Companies in the IVD Market: (% Share), 2018
Figure 3.1 Danaher: Net Sales ($bn) by Business Segment, 2017
Figure 3.2 Danaher: Revenue Shares (%) by Business Segment, 2017
Figure 3.3 Danaher: IVD Revenue ($bn) Forecast, AGR (%), 2019-2029
Figure 3.4 Danaher: IVD Market Share (%), 2019-2029
Figure 3.5 Abbott: Net Sales ($bn) by Business Segment, 2017
Figure 3.6 Abbott: Revenue Shares (%) by Business Segment, 2017
Figure 3.7 Abbott: Revenues ($bn) by Region, 2017
Figure 3.8 Abbott: Revenue Shares (%) by Region, 2017
Figure 3.9 Abbott: IVD Revenue ($bn) Forecast, AGR (%), 2019-2029
Figure 3.10 Abbott: IVD Market Share (%), 2019-2029
Figure 3.11 Bio-Rad: Historical Diagnostics Revenues ($bn) 2014-2017
Figure 3.12 Bio-Rad: Revenue Shares (%) by Business Segment, 2017
Figure 3.13 Bio-Rad: Revenue Shares (%) by Region, 2017
Figure 3.14 Bio-Rad: IVD Revenue Forecast ($bn), AGR (%), 2019-2029
Figure 3.15 Bio-Rad: IVD Market Share (%), 2019-2029
Figure 3.16 Becton Dickinson: Revenue Shares (%) by Sector, 2017
Figure 3.17 BD: Company Revenue ($bn), 2015-2017
Figure 3.18 BD IVD Revenue Forecast ($bn), AGR (%), 2019-2029
Figure 3.19 BD: IVD Market Share (%), 2019-2029
Figure 3.20 Thermo Fisher: IVD Net Sales ($bn), 2015-2017
Figure 3.21 Thermo Fisher: Revenue Shares (%) by Sector, 2017
Figure 3.22 Thermo Fisher: IVD Revenue ($bn) Forecast, AGR (%), 2019-2029
Figure 3.23 Thermo Fisher: IVD Market Share (%), 2019-2029
Figure 3.24 Thermo Fisher: Mergers & Acquisitions
Figure 4.1 Roche: Revenues ($bn) by Sector, 2017
Figure 4.2 Roche: Revenue Shares (%) by Sector, 2017
Figure 4.3 Roche Diagnostics: Revenues ($bn) by Sector, 2017
Figure 4.4 Roche Diagnostics: Revenue Shares (%) by Sector, 2017
Figure 4.5 Roche: IVD Revenue ($bn), AGR (%), Forecast, 2019-2029
Figure 4.6 Roche: IVD Market Share (%), 2019-2029
Figure 4.7 Siemens: Revenue Shares (%) by Sector, 2017
Figure 4.8 Siemens Healthcare: Revenue Shares (%) by Region, 2017
Figure 4.9 Siemens: IVD Revenue ($bn), AGR (%), Forecast 2019-2029
Figure 4.10 Siemens: IVD Market Share (%), 2019-2029
Figure 4.11 bioMérieux: Revenue ($bn) by Sector, 2017
Figure 4.12 bioMérieux: Revenue Shares (%) by Sector, 2017
Figure 4.13 bioMérieux: Clinical Applications Revenue ($bn) by Sector, 2017
Figure 4.14 bioMérieux: Clinical Applications Revenue Shares (%) by Sector, 2017
Figure 4.15 bioMérieux: IVD Revenue ($bn), AGR (%), Forecast, 2019-2029
Figure 4.16 bioMérieux: IVD Market Share (%), 2019-2029
Figure 5.1 Sysmex: Revenues ($bn) by Sector, 2017
Figure 5.2 Sysmex: Revenue Shares (%) by Sector, 2017
Figure 5.3 Sysmex: Net Sales (%) by Geographical Region, 2017
Figure 5.4 Sysmex: IVD Revenue ($bn) Forecast, AGR (%), 2019-2029
Figure 5.5 Sysmex: IVD Market Share (%), 2019-2029
Figure 5.6 Arkray: IVD Revenue ($bn) Forecast, (AGR %), 2019-2029
Figure 5.7 Arkray: IVD Market Share (%), 2019-2029
Figure 6.1 Agilent: Revenue ($bn) by Sector, 2017
Figure 6.2 Dako: Revenue Shares (%) by Sector, 2017
Figure 6.3 Genomic Health: Historical Revenues ($m) and Net Income ($m), 2013-2017
Figure 6.4 Genomic Health: Revenue Shares (%) by Reporting Segment, 2017
Figure 6.5 Genomic Health: Historical R&D Expense ($m) and R&D as a Percentage of Net Sales (%), 2013-2017
Figure 6.6 LabCorp: Historical Revenue ($bn), Profit ($bn), 2013-2017
Figure 6.7 LabCorp: Revenues ($bn) by Reporting Segment, 2017
Figure 6.8 LabCorp: Revenue Shares (%) by Reporting Segment, 2017
Figure 6.9 MDxHealth: Revenues ($m) by Reporting Segment, 2017
Figure 6.10 MDxHealth: Revenue Shares (%) by Reporting Segment, 2017
Figure 6.11 Myriad: Historical Net Revenues ($m), 2013-2017
Figure 6.12 Myriad: Revenue Shares (%) by Sector, 2017
Figure 6.13 Myriad Molecular Diagnostics: Revenue Shares (%) by Product, 2017
Figure 6.14 Myriad Molecular Diagnostics: Revenue Shares (%) by Sector, 2017
Figure 6.15 Myriad: Historical R&D Investments ($m), 2013-2017
Figure 6.16 QIAGEN: Historical Revenue ($bn), Net Income ($bn), 2013-2017
Figure 6.17 QIAGEN: Revenues ($m) by Customer Class, 2017
Figure 6.18 QIAGEN: Revenue Shares (%) by Customer Class, 2017
Figure 6.19 QIAGEN: Revenue Shares (%) by Region, 2017
Figure 6.20 QIAGEN: Historical R&D Expense ($m) and R&D Expense as a Percentage of Net Revenue (%), 2013-2017
Figure 7.1 Hologic, Inc.: Historical Revenues ($bn) and Net Income ($bn), 2013-2017
Figure 7.2 Hologic, Inc.: Revenue Shares (%) by Reporting Segment, 2017
Figure 7.3 Hologic, Inc.: Revenue Shares (%) by Reporting Segment, 2017
Figure 7.4 Hologic, Inc.: Revenue Shares (%) by Region, 2017
Figure 7.5 Hologic, Inc.: Diagnostics Revenue Shares (%), 2017
Figure 7.6 Bayer AG: Historical Revenues ($bn) and Net Income ($bn), 2013-2017
Figure 7.7 Bayer AG: Revenue Shares (%) by Reporting Segment, 2017
Figure 7.8 Bayer AG: Revenue Shares (%) by Region, 2017
Figure 7.9 PerkinElmer, Inc.: Historical Revenues ($bn), 2013-2017
Figure 7.10 PerkinElmer, Inc.: Revenue Shares (%) by Reporting Segment, 2017
Figure 7.11 PerkinElmer, Inc.: Revenue Shares (%) by Reporting Segment, 2017
Figure 7.12 PerkinElmer, Inc.: Revenue Shares (%) by Region, 2017
Figure 7.13 PerkinElmer, Inc.: Diagnostics Revenue Shares (%), 2017
Figure 7.14 DiaSorin: Historical Revenues ($m), 2013-2017
Figure 7.15 DiaSorin: Revenue Shares (%) by Region, 2017
Figure 7.16 Koninklijke Philips N.V.: Historical Revenues ($bn), 2013-2017
Figure 7.17 Koninklijke Philips N.V.: Revenue Shares (%) by Reporting Segment, 2017
Figure 7.18 Koninklijke Philips N.V.: Revenue Shares (%) by Region, 2017
Figure 7.19 Koninklijke Philips N.V.: Diagnosis & Treatment Revenue ($b), 2017
Figure 7.20 Koninklijke Philips N.V.: Diagnosis & Treatment Revenue ($bn) by Product, 2017
Figure 7.21 Koninklijke Philips N.V.: Diagnosis & Treatment Revenue Shares (%) by Product, 2017
Figure 7.22 Illumina, Inc.: Historical Revenues ($bn) and Net Income ($bn), 2013-2017
Figure 7.23 Illumina, Inc.: Revenue Shares (%) by Reporting Segment, 2017
Figure 7.24 Illumina, Inc.: Revenue Shares (%) by Region, 2017
Figure 8.1 IVD Market: Overall World Revenue ($bn), (AGR%) 2019-2029
Figure 8.2 IVD Market: Revenue ($bn) Forecasts, 2018, 2019, 2024, and 2029
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
